Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Atazanavir - Bristol-Myers Squibb

Drug Profile

Atazanavir - Bristol-Myers Squibb

Alternative Names: Atazanavir sulfate; Atazor; BMS-232632; BMS-232632-05; CGP 73547; Reyataz; TAZ

Latest Information Update: 25 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Bristol-Myers Squibb; Emcure Pharmaceuticals; Gilead Sciences
  • Class Antiretrovirals; Oligopeptides; Pyridines; Small molecules
  • Mechanism of Action HIV protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - HIV infections
  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV-1 infections

Most Recent Events

  • 07 May 2019 Launched for HIV-1 infections in Italy (PO)
  • 11 Sep 2017 Bristol-Myers Squibb completes the phase III PRINCE1 trial for HIV-1 Infections (In children, In infants, Combination therapy) in Brazil, Chile, Mexico, Peru, South Africa and Thailand, Italy and Poland (PO, Powder) (NCT01099579)
  • 10 May 2017 Bristol-Myers Squibb completes the phase III PRINCE2 trial for HIV-1 Infections (In children, In infants, Combination therapy) in USA, Argentina, Brazil, Chile, Mexico, South Africa, United Kingdom, Poland, Romania, Spain and Russia (PO) (NCT01335698)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top